NervGen Pharma Corp. (NGEN)

NCM – Цена в реальном времени. Валюта: USD

1.92

+0.03 (1.59%)

При закрытии: Jun 12, 2026, 4:00 PM EDT

2.03

+0.11 (5.73%)

До открытия: Jun 15, 2026, 7:23 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

NervGen Pharma Corp. (NGEN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

NervGen Pharma Corp. (NGEN)

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

NervGen Announces Proposed Public Offering of Securities

NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

Видео

No Data

Пресс-релизы

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

NervGen Announces Proposed Public Offering of Securities

NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

Search stocks

NervGen Pharma Corp. (NGEN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

NervGen Pharma Corp. (NGEN)

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

NervGen Announces Proposed Public Offering of Securities

NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

Видео

No Data

Пресс-релизы

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

NervGen Announces Proposed Public Offering of Securities

NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates